Related Experiment Video

Updated: Jun 3, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Therapeutic Implications of Targeting AKT Signaling in Melanoma

Subbarao V Madhunapantula1, Gavin P Robertson

  • 1Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

Enzyme Research
|April 5, 2011
PubMed

Insights

Targeting Akt3 and PTEN enzymes in the PI3K pathway may yield new melanoma treatments. Research highlights Akt3

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Melanoma progression and drug resistance are regulated by key enzymes.
  • The Akt3 pathway is crucial for melanoma cell proliferation, survival, and invasion.
  • Current therapeutic agents targeting these kinases are limited for clinical use.

Purpose of the Study:

  • To provide an overview of key PI3K pathway enzymes, focusing on Akt3 and its regulator PTEN.
  • To discuss the mechanisms regulating these enzymes and their substrates.
  • To explore the therapeutic implications of targeting Akt3 and PTEN for melanoma treatment.

Main Methods:

  • Literature review of preclinical evidence on PI3K pathway enzymes in melanoma.
  • Analysis of regulatory mechanisms and substrates of Akt3 and PTEN.
  • Discussion of current and potential therapeutic strategies targeting these proteins.

Main Results:

  • Akt3 pathway enzymes play a significant role in melanoma development.
  • PTEN acts as a negative regulator of the Akt3 kinase.
  • Targeting these enzymes offers potential for novel melanoma therapies.

Conclusions:

  • Targeting the Akt3/PTEN axis presents a promising strategy for melanoma treatment.
  • Further research is needed to identify selective and effective therapeutic agents.
  • Understanding this signaling cascade is crucial for future drug development in melanoma.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...